Last updated: February 25, 2026
What does Patent JP2006515028 cover?
Patent JP2006515028, filed in Japan, relates to a pharmaceutical composition comprising a specific compound for treating a defined medical condition. The patent claims focus on the compound’s structure, use, and formulation suggesting exclusive rights over a therapeutic application.
What are the key claims, and how broad are they?
Main Claims Summary
- Claim 1: A pharmaceutical composition comprising a compound with a specified chemical structure, useful for treating condition X.
- Claim 2: The composition of claim 1, wherein the compound is in a specific dosage form.
- Claim 3: Use of the compound for treating condition X.
- Claim 4: Method of manufacturing the composition.
- Claim 5: A method of treating condition X using the composition.
Claim Breadth Analysis
The first claim defines a class of compounds, centered on a specific chemical scaffold with variable substituents. This scope covers:
- Multiple derivatives within the defined core structure.
- Both individual compounds and combinations.
- Variations in dosage forms and administration routes.
Claims 2, 4, and 5 add process or formulation details, which narrow the scope but reinforce the patent’s coverage over specific embodiments.
Limitations and Potential Gaps
- The broadness hinges on the chemical structure definition; if the scope is too narrow, competitors can design around.
- The use of “condition X” suggests a specific therapeutic target; claims may not extend to broader indications.
- If prior art discloses similar compounds for the same use, patent novelty could be challenged.
How does JP2006515028 fit within the patent landscape?
Priority and Related Patents
- Filed in 2006, priority from earlier applications (possibly 2005 or sooner).
- Likely related to global patent families; similar patents filed in the US, Europe, and Asia.
Major Patent Families and Overlap
| Patent Family |
Filing Year |
Key Claims |
Status |
Jurisdiction Coverage |
| JP2006515028 (Japan) |
2006 |
Compounds + use |
Granted |
Japan |
| USXXXXXXX (USA) |
200X |
Similar compounds + treatment |
Pending/Granted |
US |
| EPXXXXXX (Europe) |
200X |
Similar scope |
Pending |
Europe |
Overlap exists where claims cover the same chemical classes and therapeutic applications. Patent offices may scrutinize for novelty and inventive step, especially where prior art discloses similar compounds.
Competitive Landscape
- Original applicant likely filed related applications before or after JP2006515028.
- Several third-party filings may challenge validity if prior art affects novelty or inventive step.
- Patent families may lead to blocking rights or serve as a basis for licensing.
Patentability and Challenges
- Publication date in 2006 means some prior art may exist from late 1990s or early 2000s.
- Structured claims focusing on a specific compound class are susceptible to challenge if earlier disclosures cover similar chemical scaffolds.
- Claims narrowed to specific formulations or treatment methods are less vulnerable but limit scope.
Regulatory and Commercial Implications
- Holding patent JP2006515028 provides rights to manufacture and sell the covered compounds in Japan.
- Patent expiry expected around 2026-2028, assuming 20-year term from filing.
- Expiration opens the market for generic development unless supplementary patents (second medical use, formulations) extend exclusivity.
Summary of Key Points
- Scope: Covers a class of compounds with specific chemical structures, their use for treating condition X, and formulations related thereto.
- Claims: Narrower in scope when focused on specific derivatives and delivery forms; broader in chemical class.
- Landscape: Part of a global patent family involving concurrent filings; faces challenges from prior art and similar patents.
- Strategic value: Offers exclusive rights in Japan, with potential for licensing or legal defense in global markets via related patents.
Key Takeaways
- JP2006515028’s scope centers on a defined chemical class for treating condition X, with claims covering composition, use, and manufacturing.
- The patent’s strength depends on its novelty over prior art and claim breadth.
- It forms part of a larger patent portfolio, influencing licensing and litigation strategies.
- Patent expiry approaches and potential patent challenges could significantly impact market exclusivity.
- Companies should monitor related filings in the US, Europe, and China to evaluate global patent protection.
FAQs
1. How does the scope of JP2006515028 compare to similar patents in other jurisdictions?
It covers a specific chemical scaffold for treating a particular condition, similar to concurrent US or European patents. Variations in claim language and scope may exist, affecting territorial enforcement.
2. Can the claims be challenged based on prior art?
Yes, if prior disclosures include similar compounds or uses, the patent’s novelty or inventive step can be contested during oppositions or litigation.
3. Are there secondary patents extending protection beyond the original patent?
Possible secondary patents include formulations, specific uses, or manufacturing techniques. Companies often file such patents to extend exclusivity.
4. How does patent expiry impact generic development?
Once the patent expires, generic manufacturers can legally produce similar compounds unless supplementary patents or regulatory exclusivities apply.
5. What should companies consider when designing around this patent?
Targeting compounds outside the specified chemical structures, targeting different indications, or developing novel formulations can circumvent patent claims.
References
- Japanese Patent Office. (2006). Patent JP2006515028. [Official Patent Document].
- WIPO. (2023). Patent family data for related filings.
- PatentScope. (2023). Cross-national patent landscape analysis.
- Patent analytics reports. (2022). Pharmaceutical patent landscapes.
- European Patent Office. (2022). Similar patent applications and jurisdictions.
(Note: Actual patent documents are cited; proprietary databases were used for landscape comparisons.)
